Etoposide in Treating Young Patients With Relapsed Ependymoma
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00278252
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Brief Summary
RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.
- Detailed Description
OBJECTIVES:
Primary
* Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide.
Secondary
* Determine the possibility of second surgery or additional radiotherapy in these patients.
OUTLINE: This is a multicenter study.
Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical resection.
After completion of study treatment, patients are followed periodically for approximately 5 years.
PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 14
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate by MRI after course 3
- Secondary Outcome Measures
Name Time Method Second surgery or additional radiotherapy in responding patients as assessed by MRI scan after course 3 or 6
Trial Locations
- Locations (1)
Leeds Cancer Centre at St. James's University Hospital
🇬🇧Leeds, England, United Kingdom